Long term weight reduction has been associated with favourable effects on many cardiovascular risk factors. Orlistat administration in obese patients has been associated with improvement of glucose tolerance and reduction in the incidence of type 2 diabetes. Furthermore, well conducted trials demonstrated the ability of orlistat to reduce many cardiovascular risk factors: hypertension, total and low density lipoprotein (LDL) cholesterol levels and low density lipoprotein cholesterol/high density lipoprotein cholesterol ratio (LDL/HDL ratio). More recently orlistat has yet been involved in the modulation of some inflammatory markers. Data available from intervention trials suggest that weight loss reduces coronary heart disease risk factors in obese persons and the risk factor reduction is significantly enhanced with administration of orlistat.
|Translated title of the contribution||Orlistat and cardiovascular risk|
|Number of pages||10|
|Journal||Trends in Medicine|
|Publication status||Published - Apr 2006|
ASJC Scopus subject areas
- Internal Medicine
- Pharmacology (medical)